Skip to content
Menu

Dyadic International, Inc. DYAI

Full chart Compare
Set alert

Price alert · DYAI

All alert types
0.32 USD -0.01 (-2.14%)

Regular-session close

0.35 +0.03 +9.37%

After hours · Nov 16, 4:00 PM ET

0.3002 Day range 0.3499
0.3002 52-week range 1.60
YTD
-65.96%
1 year
-64.84%
Market cap
12.82M
Revenue (ttm)
1.80M
EPS (ttm)
-0.23
Shares out
29.59M
Forward P/E
-5.59
YTD return
-65.96%
1-year return
-64.84%
50-day average
1.36
Volume
74.71K
Avg volume
145.37K
Open
0.333
Previous close
0.327
Day's range
0.3002 – 0.3499
52-week range
0.3002 – 1.60
Beta
0.72
Price target
7.50 (+2243.8%)

 

No chart data for this range yet.

Key statistics

200-day average
1.48
Enterprise value
29.07M
Price / sales
29.36
Price / book
8.77
Revenue growth
-53.90%
Free cash flow
-3.49M
Total cash
10.10M
Total debt
5.56M
Return on equity
-127.38%
Short % of float
0.89%

Fundamental scorecard

7 of 25 checks passed on DYAI’s reported financials

ValueGrowthProfitabilityHealthDividend

7of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
DYAI Revenue — quarterly 449.10K
DYAI Net income — quarterly -1.36M
DYAI EPS — quarterly -0.04

Earnings

DYAI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.07-0.01+0.06+85.71%
Aug 13, 2024Jun 1, 2024-0.07-0.070.000.00%
May 14, 2024Mar 1, 20240.00-0.07——
Mar 28, 2024Dec 1, 2023-0.07-0.08-0.01-14.29%
Nov 8, 2023Sep 1, 2023-0.06-0.060.000.00%
Aug 9, 2023Jun 1, 2023-0.05-0.07-0.02-40.00%

Upgrades / downgrades

DYAI analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024HC Wainwright & Co.reitBuyBuy
Jul 8, 2024HC Wainwright & Co.reitBuyBuy
Nov 13, 2023HC Wainwright & Co.reitBuyBuy
May 24, 2023HC Wainwright & Co.reitBuyBuy
Feb 3, 2023HC Wainwright & Co.reit—Buy
Jul 18, 2022Dawson JamesdownBuyNeutral

About Dyadic International, Inc.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
dyadic.com

News

Your note

Sign in to keep a note on DYAI — it syncs with the Stock Master app.

Insider holders

DYAI insider holders
InsiderRelationLatest transactionDateShares held
BOSE ARINDAMDirectorConversion of Exercise of derivative securityJan 2, 202427,174
BUCKLAND BARRY JOHNDirectorConversion of Exercise of derivative securityJun 10, 202438,967
EMALFARB MARK AChief Executive OfficerStock Award(Grant)Mar 12, 20244,656,950
HAZELTON JOSEPH POfficerStock Award(Grant)Mar 12, 202499,168
HERBST SETH J. M.D.DirectorConversion of Exercise of derivative securityJan 2, 2024132,174
KAYE JACKDirectorConversion of Exercise of derivative securityJan 2, 202433,581

Institution ownership

DYAI institution ownership
Holder% heldSharesValueReported
Bandera Partners LLC5.87%1,566,9082.80MSep 29, 2024
Chapin Davis, Inc.3.25%868,3011.55MSep 29, 2024
Vanguard Group Inc3.02%805,8081.44MSep 29, 2024
Blackrock Inc.0.96%255,800457.88KSep 29, 2024
Northeast Financial Consultants Inc0.94%250,000447.50KSep 29, 2024
Geode Capital Management, LLC0.90%240,175429.91KSep 29, 2024

Fund ownership

DYAI fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.23%596,3831.07MSep 29, 2024
Vanguard Extended Market Index Fund0.60%161,079288.33KSep 29, 2024
Fidelity Extended Market Index Fund0.42%113,483203.13KOct 30, 2024
iShares Micro Cap ETF0.19%52,01993.11KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.18%48,86687.47KOct 30, 2024
Fidelity Total Market Index Fund0.14%37,64267.38KOct 30, 2024